These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 34830853)

  • 1. Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors.
    Larribère L; Martens UM
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review.
    Zhu L; Xu R; Yang L; Shi W; Zhang Y; Liu J; Li X; Zhou J; Bing P
    Front Genet; 2023; 14():1172108. PubMed ID: 37636270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives.
    Peng Y; Mei W; Ma K; Zeng C
    Front Oncol; 2021; 11():763790. PubMed ID: 34868984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review).
    Chen H; Zhou Q
    Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma.
    Fu Y; Xu Y; Liu W; Zhang J; Wang F; Jian Q; Huang G; Zou C; Xie X; Kim AH; Mathios D; Pang F; Li F; Wang K; Shen J; Yin J
    EClinicalMedicine; 2024 Jul; 73():102697. PubMed ID: 39022798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
    Tarazona N; Gimeno-Valiente F; Gambardella V; Zuñiga S; Rentero-Garrido P; Huerta M; Roselló S; Martinez-Ciarpaglini C; Carbonell-Asins JA; Carrasco F; Ferrer-Martínez A; Bruixola G; Fleitas T; Martín J; Tébar-Martínez R; Moro D; Castillo J; Espí A; Roda D; Cervantes A
    Ann Oncol; 2019 Nov; 30(11):1804-1812. PubMed ID: 31562764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck.
    Honoré N; van Marcke C; Galot R; Helaers R; Ambroise J; van Maanen A; Mendola A; Dahou H; Marbaix E; Van Eeckhout P; Longton E; Magremanne M; Schmitz S; Limaye N; Machiels JP
    Ann Oncol; 2023 Dec; 34(12):1175-1186. PubMed ID: 37879442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
    Shields MD; Chen K; Dutcher G; Patel I; Pellini B
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease.
    Moding EJ; Nabet BY; Alizadeh AA; Diehn M
    Cancer Discov; 2021 Dec; 11(12):2968-2986. PubMed ID: 34785539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions.
    Chae YK; Oh MS
    J Thorac Oncol; 2019 Jan; 14(1):16-24. PubMed ID: 30296486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact.
    Honoré N; Galot R; van Marcke C; Limaye N; Machiels JP
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC).
    Chakrabarti S; Kasi AK; Parikh AR; Mahipal A
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal Residual Disease Monitoring in Radically Treated Non-Small Cell Lung Cancer: Challenges and Future Directions.
    O'Sullivan HM; Feber A; Popat S
    Onco Targets Ther; 2023; 16():249-259. PubMed ID: 37056631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?
    Solar Vasconcelos JP; Boutin M; Loree JM
    Ther Adv Med Oncol; 2022; 14():17588359221143975. PubMed ID: 36570410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine.
    Pellini B; Pejovic N; Feng W; Earland N; Harris PK; Usmani A; Szymanski JJ; Qaium F; Mudd J; Petty M; Jiang Y; Singh A; Maher CA; Henke LE; Park H; Ciorba MA; Kim H; Mutch MG; Pedersen KS; Tan BR; Hawkins WG; Fields RC; Chaudhuri AA
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC).
    Masfarré L; Vidal J; Fernández-Rodríguez C; Montagut C
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34201274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.
    Abbosh C; Birkbak NJ; Swanton C
    Nat Rev Clin Oncol; 2018 Sep; 15(9):577-586. PubMed ID: 29968853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization of tissue-free minimal residual disease testing in colorectal cancer patients from Asia and Middle East.
    Jain S; Dawood S; Lavingia V; Aderka D; Tahover E; Hsieh YY; Temper M; Goldman A; Akasheh MA; Olsen S; Hsing SS; Joshi N; Jen HY
    Front Oncol; 2024; 14():1426941. PubMed ID: 39372864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection.
    Xu Y; Cai J; Zhong K; Wen Y; Cai L; He G; Liao H; Zhang C; Fu S; Chen T; Cai J; Zhong X; Chen C; Huang M; Cheng Y; Pan M
    Front Oncol; 2023; 13():1119744. PubMed ID: 36959801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.